Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of guselkumab in moderate to severe palmoplantar pustulosis
2018-004451-20Phase 2Completed
- Sponsor
- University of Bonn
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guselkumab in Palmoplantar Pustular Psoriasis (PPPP), sponsored by University of Bonn. Primary endpoint: Change in ppPASI score at week 24. Started Apr 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2018-004451-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004451-20.